Clinical trials: Human Immunodeficiency Virus Type 1
HIV-1 Infection, Receipt of Cal-1 Modified Hematopoietic Cellular Products
Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients
Long term safety follow-up of Cal-1 recipients
- Trial name
- NCT02390297
- Testing
- Blood tests
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Calimmune, Inc.
Human Immunodeficiency Virus
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection
This is an early phase research study looking at whether an experimental gene transfer, LVsh5/C46 (also known as Cal-1), is safe and if it can protect the immune system from the effects of HIV without the use of antiretroviral…
- Trial name
- NCT01734850
- Testing
- Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Calimmune, Inc.
Human Immunodeficiency Viruses
Implementing Long-Acting Novel Antiretrovirals
This is a 12-month, dual arm, phase 4, open-label, multi-centre study examining the implementation of LA intra-muscular (IM) drugs in clinics and decentralised community-based settings in the UK.
- Trial name
- ILANA (NCT05294159)
- Testing
- The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)
- Where
- 6 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- Queen Mary University of London
Human Immunodeficiency Virus, Immune Reconstitution Inflammatory Syndrome
Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)
Design: Randomized clinical trial involving hospitalized HIV-1 infected children. Children will be randomized to randomized to urgent (<48 hours) versus early antiretroviral therapy (7-14 days). This trial will be unblinded.
- Trial name
- PUSH (NCT02063880)
- Testing
- Urgent ART, Early ART
- Where
- 4 sites in Kenya
- Volunteers
- 183 people
- Sponsor
- University of Washington
HIV Infections, Pregnancy
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns
Part 1: To determine both the safety, tolerance, and pharmacokinetic profile (blood levels) of recombinant CD4 immunoglobulin G (rCD4-IgG) by intravenous bolus administration (given through the vein) in women with HIV infection…
- Trial name
- NCT00000642
- Testing
- CD4-IgG
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs
For PRAM-1: To evaluate zidovudine (ZDV) + lamivudine (3TC) vs. stavudine (d4T) + ritonavir vs. ZDV + 3TC + ritonavir with respect to the change in plasma HIV-1 RNA copy number from baseline to 48 weeks [AS PER AMENDMENT 1/5/98…
- Trial name
- NCT00001083
- Testing
- Indinavir sulfate, Ritonavir, Nevirapine
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infections
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
This study will evaluate the efficacy of Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF)) single-tablet regimen (STR) after switching from a regimen consisting of raltegravir plus…
- Trial name
- NCT01533259
- Testing
- Stribild
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
HIV-1-infection, Hiv
Studying Topiramate for Re-Activating the HIV-1 Reservoir
Even with current HIV treatments, HIV is still a lifelong disease because it hides in some long-lasting cells in the body. One of the strategies to find a cure for HIV works by finding the virus in these cells, making it visible…
- Conditions
- HIV-1-infection, Hiv, HIV Infections, HIV I Infection
- Trial name
- STAR (NCT06282783)
- Testing
- Topiramate
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Erasmus Medical Center
HIV
Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)
RESEARCH METHODS Study Design Observational, Retrospective, Single-center, Single-arm Study of patients treated with raltegravir plus abacavir and lamivudine.
- Trial name
- NCT02708342
- Volunteers
- 100 people
- Sponsor
- IRCCS San Raffaele
Acquired Immunodeficiency Syndrome, HIV Infections
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
This study is to evaluate the safety and tolerability of cobicistat-boosted darunavir plus two fully active nucleoside analogue reverse transcriptase inhibitors in HIV 1 infected, antiretroviral treatment-naive and…
- Trial name
- NCT01440569
- Testing
- COBI, DRV, NRTIs
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- Gilead Sciences
HIV/AIDS
Dolutegravir Plus Lamivudine Simplified Therapy
Dolutegravir (DTG) is one type of integrase inhibitor, lamivudine (3TC) is one type of reverse transcriptase inhibitor, both of which are HIV medicine prevents HIV from self-multiplying, reduces the viral load.
- Trial name
- NCT03884673
- Testing
- DTG+ 3TC
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Guangzhou 8th People's Hospital
HIV
Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in Africa
An Experimental Medicine Vaccine Trial of Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in Africa, Randomized for Assessment of Fractional Doses.
- Trial name
- C112 (NCT06449196)
- Testing
- Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM), : Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)
- Sponsor
- International AIDS Vaccine Initiative
HIV-1-infection
Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study
The goal of this randomized, single blind, two-armed pilot study is to assess the efficacy of FMT in reducing gut mucosal and systemic inflammation in ART-treated people living with HIV with low CD4/CD8 ratio.
- Trial name
- Gutsy (NCT06022406)
- Testing
- FMT capsules
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Jean-Pierre Routy
HIV Infections
Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
This study aimed to evaluate the safety, tolerability, and pharmacokinetics of maraviroc in infants at risk for mother-to-child HIV transmission, and to determine an appropriate dose of maraviroc during the first six weeks of…
- Trial name
- NCT02778204
- Testing
- Maraviroc
- Where
- 9 sites in United States, Kenya and 2 more
- Volunteers
- 47 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pregnancy, HIV-1-infection
Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)
This trial is a prospective, multi-center, randomized comparison study of 2 Pre-Exposure Prophylaxis (PrEP) pharmacokinetic (PK) dosing regimens from 1st trimester through 12 weeks following delivery (postpartum) to achieve study…
- Trial name
- NCT03834909
- Testing
- Standard dose Truvada®, Pregnancy-adjusted dose Truvada®
- Volunteers
- healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infections
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
This study will assess the safety and efficacy of once-daily administration of Fuzeon compared with twice-daily administration in HIV-1 infected patients who have received prior treatment.
- Trial name
- NCT00089492
- Testing
- Optimized Background ARVs, enfuvirtide [Fuzeon]
- Where
- 27 sites in United States, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
HIV Infections, Lymphoma
Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma
This pilot clinical trial studies gene therapy in treating patients with HIV-1 infecetion combined with lymphoma undergoing 7shRNA lentiviral vector transduced CD34+ hematopoietic stem cell transplant.
- Trial name
- NCT05922384
- Testing
- KL-7SHRNA injection solution
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
HIV-1-infection, Aging
Fitness and Longevity in Exercise
The study objective was to determine the safety and efficacy of aerobic exercise in older HIV-infected men in a randomized trial comparing different levels of exercise intensity.
- Trial name
- FLEX (NCT03399136)
- Testing
- Exercise training
- Volunteers
- 31 people
- Sponsor
- University of Maryland, Baltimore
Infection, Human Immunodeficiency Virus, HIV Infections
Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection
HIV/Tuberculosis (TB) co-infection have profound effects on the host's immune system. TB is the most common cause of death in patients with HIV worldwide.
- Trial name
- NCT02178592
- Testing
- DTG 50 mg, EFV 600 mg
- Where
- 28 sites in Argentina, Brazil and 5 more
- Volunteers
- 113 people
- Sponsor
- ViiV Healthcare
HIV Infections
Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein
This Phase I study is directed at evaluating the safety profile (as a primary end-point) and the immunogenicity (as a secondary end-point) of the recombinant HIV-1 Tat vaccine in healthy, immunologically competent adult subjects…
- Trial name
- ISSP-001 (NCT00529698)
- Testing
- Biologically active recombinant Tat protein
- Where
- 4 sites in Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Istituto Superiore di Sanità
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.